帕布昔利布杂质23

中文名称:

帕布昔利布杂质23

中文同义词:

4-[6-[(6-溴-8-环戊基-7,8-二氢-5-甲基-7-氧代吡啶并[2,3-D]嘧啶-2-基)氨基]-3-吡啶基]-1-哌嗪羧酸叔丁酯;4-[6-[(6-溴-8-环戊基-7,8-二氢-5-甲基-7-氧代吡啶并[2,3-D]嘧啶-2-基)氨基]-3-吡啶;帕布昔利布中间体1;4-[6-[(6-溴-8-环戊基-7,8-二氢-5-甲基-7-氧代吡啶并[2,3-D]嘧啶-2-基)氨基]-3-吡啶基]-1-哌嗪羧酸叔丁酯 哌泊塞克雷布中间体 1KG;4-[6-(6-溴-8-环戊基-5-甲基-7-氧代-7,8-二氢吡啶并[2,3-D]嘧啶- 2-基氨基)-吡啶-3-基]-哌嗪-1-羧酸叔丁酯;帕布昔利布中间体6;(3E)-1-(2-氯乙酰基)-2,3-二氢-3-(甲氧基苯基亚甲基)-2-氧代-1H-吲哚-6-羧酸甲酯;帕布昔利布中间体一

英文名称:

4-[6-(6-BROMO-8-CYCLOPENTYL-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO)-PYRIDIN-3-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER

英文同义词:

4-[6-(6-BROMO-8-CYCLOPENTYL-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO)-PYRIDIN-3-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 4-(6-((6-broMo-8-cyclopentyl-5-Methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyriMidin-2-yl)aMino)pyridin-3-yl)piperazine-1-carboxylate;1-Piperazinecarboxylic acid, 4-[6-[(6-broMo-8-cyclopentyl-7,8-dihydro-5-Methyl-7-oxopyrido[2,3-d]pyriMidin-2-yl)aMino]-3-pyridinyl]-, 1,1-diMethylethyl ester;4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester;4- [6- (6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido [2,3-d] pyrimidin -2- ylamino) - pyridine 3-yl] - piperazine-1- carboxylic acid tert-butyl ester;tert-butyl 4-{6-[(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl}piperazine-1-carboxylat;tert-butyl 4-[6-[(6-bromo-8-cyclopentyl-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazine-1-carboxylate;tert-Butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)

CAS号:

571188-82-4

分子式:

C27H34BrN7O3

分子量:

584.51

EINECS号:

1592732-453-0

相关类别:

医药中间体;帕布昔利布中间体;帕博西尼中间体;帕博西布中间体;对照品-杂质对照品;杂质对照品;Palbociclib;PD 0332991;Anticancer

Mol文件:

Mol File

熔点 

>250℃

沸点 

720.0±70.0 °C(Predicted)

密度 

1.439±0.06 g/cm3(Predicted)

储存条件 

Keep in dark place,Sealed in dry,2-8°C

酸度系数(pKa)

5.24±0.10(Predicted)

用途

帕布昔利布杂质23是帕布昔利的杂质，是辉瑞公司开发的治疗乳腺癌的实验药物。它是细胞周期素依赖性激酶CDK4和CDK6的选择性抑制剂。此外，它衍生自6-溴-2-氯-8-环戊基-5-甲基吡啶-[2,3-d]嘧啶-7（8H）-酮, 用于制备吡啶基[2,3-d]嘧啶-7（8H）-酮衍生物，作为CDK4和/或用于治疗疾病的CDK6抑制剂。